Since the dominant action of class III antiarrhythmic agents is to lengthen the APD by a reduction of IKr, it is thought that the therapeutic effect of the agents against arrhythmia in the study subjects is manifested by offsetting oversupplied KCNH2 currents. This evidence concerns the gene KCNH2 and cardiac arrhythmia.